Skip to main content
. Author manuscript; available in PMC: 2015 Jan 13.
Published in final edited form as: Oncogene. 2013 Mar 11;33(10):1306–1315. doi: 10.1038/onc.2013.59

Figure 1. Increased expression of PKCδ negatively correlates with prognosis in ErbB2 positive human breast cancer.

Figure 1

A. Overexpression (red) and underexpression (blue) of PKCδ in 21 human breast cancer data sets. Intensity of the cell color corresponds to the top percentage of ranked genes, with 50% (white) representing no change between tumor sets. The median rank for PKCδ overexpression in ErbB2 positive tumors across each data set is 2,871 (P=0.01), while the underexpression median rank is 13,701 (P=0.827). B, C, and D. Kaplan-Meier analysis, using relapse-free survival as endpoint, for (B) ErbB2 positive tumors (four data sets, n= 122, P=0.017), (C) All molecular subtypes (four data sets, n= 914, P=0.0002), and (D) Triple-negative (ER-/PR-/ErbB2-)(four data sets, n=143, P=0.488), stratified into two quantiles base on high (red line) or low (gray line) PKCδ expression.